PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

Stock Information for PhaseBio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.